Dr Ben Herbert leads the Sangui Bio research group at the Kolling Institute based at Royal North Shore Hospital. 

Co-Founder & Chief Scientific Officer

in

Dr Herbert is a protein biochemist with over 25 years of experience in technology development and commercialisation and has co-founded two ASX listed companies in the biotech/healthcare industry. He has broad experience in securing investment for companies in the biotech/healthcare industry and a track record of creating, protecting, and commercialising intellectual property. He has developed and commercialised biotechnology products with multinational partners, such as Bio-Rad and Sigma-Aldrich, and his co-founded companies – Proteome Systems, Regeneus and Sangui Bio.

​

In 1999, he co-founded the biotechnology company Proteome Systems, where he served full time as Head of Sample Preparation until 2006. He played an active role in establishing and managing Proteome Systems IP portfolio.

​

In 2007 Ben was a co-founder of Regeneus Ltd, a regenerative medicine company that has developed and commercialised stem cell therapies using adipose derived cells. Ben served as a non-executive Director of Regeneus from startup through ASX listing in 2013 and left the Board to pursue the opportunities that became Sangui Bio in late 2014. He maintains strong connections to Regeneus Ltd.

Dr Herbert has 8 granted patents on proteomics technology (US, EU, AU) owned by Macquarie University and Proteome Systems. He has developed IP (patents pending) with Regeneus on inflammatory biomarkers to monitor disease progression and the effect of mesenchymal stem cell therapy. He is also an inventor on four families of granted patents and pending applications covering the Sangui Bio discoveries. Dr Herbert has significant experience with assessment of the IP landscape in various research areas; including instrumentation, consumables and biologicals, patent drafting/filing, due diligence, and patent challenges.

Ben Herbert has 37 years of experience in protein chemistry, sample preparation, fractionation, and proteomics. He has gained international recognition as one of key innovators in sample preparation, fractionation and the use of proteomics. Ben has 92 research, review papers and book chapters. His research papers and chapters have been cited 7300 times and his H-index measurement of research impact is 40. Dr Herbert has supervised 9 PhD students to completion and currently co-supervises 1 PhD student.